Your browser doesn't support javascript.
loading
History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.
Minlikeeva, Albina N; Freudenheim, Jo L; Cannioto, Rikki A; Szender, J Brian; Eng, Kevin H; Modugno, Francesmary; Ness, Roberta B; LaMonte, Michael J; Friel, Grace; Segal, Brahm H; Odunsi, Kunle; Mayor, Paul; Zsiros, Emese; Schmalfeldt, Barbara; Klapdor, Rüdiger; DÓ§rk, Thilo; Hillemanns, Peter; Kelemen, Linda E; KÓ§bel, Martin; Steed, Helen; de Fazio, Anna; Jordan, Susan J; Nagle, Christina M; Risch, Harvey A; Rossing, Mary Anne; Doherty, Jennifer A; Goodman, Marc T; Edwards, Robert; Matsuo, Keitaro; Mizuno, Mika; Karlan, Beth Y; Kjær, Susanne K; Høgdall, Estrid; Jensen, Allan; Schildkraut, Joellen M; Terry, Kathryn L; Cramer, Daniel W; Bandera, Elisa V; Paddock, Lisa E; Kiemeney, Lambertus A; Massuger, Leon F; Kupryjanczyk, Jolanta; Berchuck, Andrew; Chang-Claude, Jenny; Diergaarde, Brenda; Webb, Penelope M; Moysich, Kirsten B.
Afiliação
  • Minlikeeva AN; Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
  • Freudenheim JL; Deparment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY, USA.
  • Cannioto RA; Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
  • Szender JB; Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Eng KH; Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Modugno F; Department of Epidemiology, University of Pittsburgh, and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Ness RB; Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • LaMonte MJ; Department of Obstetrics, Gynecology and Reproductive Sciences and Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Friel G; The University of Texas, School of Public Health, Houston, TX, USA.
  • Segal BH; Deparment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY, USA.
  • Odunsi K; Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
  • Mayor P; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Zsiros E; Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Schmalfeldt B; Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Klapdor R; Center of Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • DÓ§rk T; Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Hillemanns P; Center of Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Kelemen LE; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • KÓ§bel M; Department of Obstetrics and Gynecology, Hannover Medical School, Hanover, Lower Saxony, Germany.
  • Steed H; Department of Obstetrics and Gynecology, Hannover Medical School, Hanover, Lower Saxony, Germany.
  • de Fazio A; Department of Obstetrics and Gynecology, Hannover Medical School, Hanover, Lower Saxony, Germany.
  • Jordan SJ; Department of Pathology and Laboratory Medicine, Foothills Medical Center, University of Calgary, Calgary, AB, Canada.
  • Nagle CM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Royal Alexandra Hospital, Edmonton, AB, Canada.
  • Risch HA; Department of Gynecological Oncology, Westmead Hospital and the Westmead Millenium Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.
  • Doherty JA; Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Goodman MT; Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Edwards R; School of Public Health, The University of Queensland, Brisbane, QLD, Australia.
  • Matsuo K; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
  • Mizuno M; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Karlan BY; Department of Epidemiology, The Geisel School of Medicine at Dartmouth Medical, Hanover, NH, USA.
  • Kjær SK; Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Høgdall E; Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Jensen A; Department of Obstetrics, Gynecology and Reproductive Sciences and Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Schildkraut JM; Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan.
  • Terry KL; Department of Gynecological Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
  • Cramer DW; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Bandera EV; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Paddock LE; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Kiemeney LA; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Massuger LF; Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Kupryjanczyk J; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Berchuck A; Department of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, VA, USA.
  • Chang-Claude J; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Diergaarde B; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Webb PM; Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Moysich KB; New Jersey Department of Health and Senior Services, Trenton, NJ, USA.
Cancer Causes Control ; 28(5): 469-486, 2017 May.
Article em En | MEDLINE | ID: mdl-28293802
ABSTRACT

PURPOSE:

Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.

METHODS:

Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.

RESULTS:

History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.

CONCLUSIONS:

Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cardiopatias / Hipertensão Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Causes Control Assunto da revista: EPIDEMIOLOGIA / NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cardiopatias / Hipertensão Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Causes Control Assunto da revista: EPIDEMIOLOGIA / NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos